Our mission is to develop
and commercialize novel
and best-in-class therapeutics
to address unmet medical needs
in the emerging otology market

AuriPro™

A sustained-exposure formulation of the antibiotic ciprofloxacin that has been submitted to FDA for approval as a treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement (TTP) surgery...
LEARN MORE »

OTO-104

A sustained-exposure formulation of the steroid dexamethasone that is in a Phase 2b clinical trial for patients with Ménière’s disease...
LEARN MORE »

OTO-311

A sustained-exposure formulation of the NMDA receptor antagonist gacyclidine in development for the treatment of tinnitus...
LEARN MORE »